FDA Invites Comment on Drug Testing Guidance for Early AD
Scientists have turned their attention toward testing therapies in early-stage patients who have underlying brain pathology but little to no functional impairment...
ALL NEWS
5781 RESULTS
Sort By:
- Most Recent
- Most Commented
Inventory of Tau Modifications Hints at Undiscovered Functions
A new mass spectrometry analysis provides the most thorough catalog yet of modifications to tau.
Peripheral Aβ Can Accumulate in Brain, Trigger Degeneration
Wild-type mice exposed to blood from Alzheimer’s amyloidosis mice developed plaques, tau phosphorylation, neuroinflammation, and synaptic deficits.
Scratch Lanabecestat: This BACE Inhibitor Doesn’t Work in Symptomatic AD, Either
After veru- and atabecestat, now a third β-secretase inhibitor, by Eli Lilly and AstraZeneca, is being pulled from ongoing Phase 3 trials of symptomatic Alzheimer’s disease.
When Host Proteins Coat Virus, Amyloid Fibrils Form
Viral surfaces attract proteins from the extracellular environment of the person they infect. This corona of host proteins makes the virus more or less infective—and promotes amyloid fibrils.
San Diego: Treating Forgetfulness—Triple Transgenics Provoke
A mouse model that mimics both signature pathologies of Alzheimer disease develops a day-to-day forgetfulness at four months...
Fats, Aβ, Oxidative Stress: Feeding Forward and Backward, Killing Neurons?
Add a new strand to the growing web of relationships among production of the Aβ peptide, regulation of cholesterol and other lipids, oxidative stress, and the death of neurons in Alzheimer's. Researchers believe that Aβ drives an increase in the conversion of...
Lilly Halts IDENTITY Trials as Patients Worsen on Secretase Inhibitor
Eli Lilly and Company announced yesterday that it has halted its Semagacestat γ-secretase inhibitor program...
Law and Disorder—APPswe Patent Suits Raise Ruckus Again
The fight against Alzheimer disease rallies warriors of many sorts...
NIH Director Announces $100M Prevention Trial of Genentech Antibody
Francis Collins announced that $16 million of federal funds would go toward the first-ever therapeutic prevention trial in cognitively healthy people...
San Diego: Oligomers Live Up to Bad Reputation, Part 1
Over the past decade, researchers have shifted away from a literal interpretation of Alois Alzheimer’s groundbreaking discovery...
Breakthrough or False Hope? Etanercept Case Report Draws Scrutiny
Can an FDA-approved arthritis drug double as a therapy for Alzheimer disease?...
Target BACE: Better Than Ever?
In yesterday’s Neuron, researchers presented fresh in-vivo support for the amyloid hypothesis and bolster the status of the APP protease BACE as the current favorite target for AD therapy development...
Antibodies Stop Toxic Tau in Its Extracellular Tracks
Antibodies against extracellular tau block seeding, diminish brain pathology, and may improve cognition in a mouse model.
Mistakes Prompt Retraction of Controversial Paper, and Publication Ban
The Journal of Neuroscience retracted a paper that claimed Aβ does not accumulate inside neurons, and temporarily banished its senior authors.
Current Filters
- Date Range : All x